Generic Drug Development CDMO

Introduction A peptide purity testing report, commonly presented as a Certificate of Analysis (CoA) or analytical datasheet, is a critical […]

Introduction When a Complete Response Letter (CRL) is issued for a Generic ANDA under 21 CFR 314.110, the applicant immediately

Introduction The choice between the 505(b)(2) vs ANDA Regulatory Pathway depends largely on whether the proposed drug product is an

Introduction Pharmaceutical sponsors can execute a Switch CDMO After ANDA Submission, but the regulatory approach depends on whether the ANDA

Introduction An Abbreviated New Drug Application (ANDA) submission requires stability data from a minimum of three primary exhibit batches, which

Introduction: CDMO support for ANDS can provide generic drug sponsors with the scientific, analytical, manufacturing, and documentation capabilities needed to

Introduction: For any company preparing to file an Abbreviated New Drug Application (ANDA), a Comparative Dissolution Study for ANDA is

Introduction Scaling a GLP-1 analog from preclinical synthesis to Good Manufacturing Practice (GMP) kilogram-scale manufacturing involves moving beyond small-scale discovery

Introduction Supporting a poorly soluble generic API requires an integrated Chemistry, Manufacturing, and Controls (CMC) framework that combines systematic reference-listed

Introduction Executing a successful Generic Metered Dose Inhaler (MDI) ANDA Development program requires a comprehensive weight-of-evidence regulatory framework that demonstrates